Related Experiment Video
Updated: Apr 18, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Biomarker use is associated with reduced clinical trial failure risk in metastatic melanoma
Daniel A Rubinger1, Sarah S Hollmann, Viktoria Serdetchnaia
1Biology Department, University of Toronto Mississauga, William Davis Building, Room 2071, Mississauga, ON, L5L 1C6, Canada.
Abstract:
Given the high morbidity and mortality associated with metastatic melanoma, considerable attention has been paid to identifying potential therapies. Until recently, few therapies have been specifically approved for treating metastatic melanoma. In an attempt to increase clinical trial successes, many therapies are implementing biomarkers for patient stratification. This strategy narrows down the population in an effort to identify appropriate subpopulations that have increased efficacy or fewer safety concerns. However, the addition of a biomarker constitutes an additional risk to clinical development and may therefore increase the overall clinical trial risk. Here, we examine the clinical trial success rate for therapies targeting metastatic melanoma. In addition, we identify the impact that biomarkers have had on the clinical development of this disease.
Insights
This study analyzes clinical trial success rates for metastatic melanoma therapies. Biomarker use in patient stratification may increase clinical trial risks, impacting drug development for this aggressive cancer.
Area of Science:
- Oncology
- Clinical Trials
- Pharmacology
Background:
- Metastatic melanoma has high morbidity and mortality, driving the need for effective therapies.
- Few therapies have been approved for metastatic melanoma, necessitating improved drug development strategies.
- Biomarker-guided patient stratification is increasingly used to enhance clinical trial success.
Purpose of the Study:
- To examine the clinical trial success rate for therapies targeting metastatic melanoma.
- To evaluate the impact of biomarkers on the clinical development of metastatic melanoma treatments.
Main Methods:
- Analysis of clinical trial data for metastatic melanoma therapies.
- Assessment of the influence of biomarker implementation on trial outcomes.
Main Results:
- The study identifies trends in clinical trial success rates for metastatic melanoma.
- The impact of biomarkers on efficacy and safety in clinical development is quantified.
Conclusions:
- Biomarker implementation in metastatic melanoma trials presents both opportunities for targeted efficacy and potential risks to overall development.
- Understanding these impacts is crucial for optimizing future clinical trial designs and accelerating the approval of novel therapies.
